"NLRP3 Protein Inhibitors Clinical Trials"NLRP3 protein inhibitors companies are Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome ...

Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth analysis and advisory services for the evolving ...

Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...

The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS (ON) G12C-selective inhibitor, ...

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

Innovations like endoscopic imaging, AI-enhanced tools, and minimally invasive therapies are reshaping patient care. Despite challenges like public awareness gaps and cost barriers, strategic ...

As described in the abstract, investigators will present first evidence that A2B receptor inhibition reduces the adenosine-mediated increase in PD-L1 in a human epithelioid mesothelioma cell line, ...

Full year 2025 net product revenue guidance was raised to $4.23 billion to $4.32 billion, with Jakafi guidance increased to $3.05 billion to $3.075 billion. Tray affirmed, "We maintain our prior OpEx ...

Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results for the second quarter ended ...

An RNAi based genetic screen and subsequent analyses reveal how dyneins and small GTPases coordinate autophagosome positioning at the ncMTOC in fat cells, advancing understanding of autophagic vesicle ...